MarketCap
Facebook
X
Telegram
Establishment Labs Holdings Net Income | ESTA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Establishment Labs Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.1 M | -84.6 M | -78.5 M | -75.2 M | -41.1 M | -38.1 M | -38.2 M | -21.1 M | -34.9 M | -22.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.1 M | -84.6 M | -48.5 M |
Quarterly Net Income Establishment Labs Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.4 M | -11.1 M | -16.6 M | -20.7 M | - | -16.7 M | -17.2 M | -16.2 M | - | -29.3 M | -16.7 M | -11.9 M | - | -18.6 M | -37.1 M | -5.93 M | - | -14.7 M | -5.32 M | -6.95 M | - | -4.24 M | -10.5 M | -17.8 M | - | -12.8 M | -9.04 M | -10.8 M | - | 1.31 M | -5.36 M | -6.53 M | - | -10.7 M | -12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.31 M | -37.1 M | -13.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | - | - | $ 162 M |  France |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-6.09 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Myomo
MYO
|
-15.6 M | $ 1.01 | 1.0 % | $ 42.3 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
InspireMD
NSPR
|
-48.8 M | $ 0.65 | -3.68 % | $ 41.8 M |  Israel |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Profound Medical Corp.
PROF
|
-42.6 M | $ 7.38 | 1.79 % | $ 223 M |  Canada |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Quanterix Corporation
QTRX
|
-107 M | $ 3.48 | -1.14 % | $ 148 M | USA |
 |
AVITA Medical
RCEL
|
-48.6 M | $ 4.4 | -2.0 % | $ 123 M |  Australia |
 |
AxoGen
AXGN
|
-15.7 M | $ 42.21 | 2.08 % | $ 1.94 B | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
Bruker Corporation
BRKR
|
-8.3 M | $ 62.84 | -2.33 % | $ 9.54 B | USA |
 |
Smith & Nephew plc
SNN
|
625 M | $ 31.56 | -2.46 % | $ 27.4 B |  Britain |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Tactile Systems Technology
TCMD
|
19.1 M | $ 28.17 | -0.11 % | $ 644 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
TELA Bio
TELA
|
-38.8 M | $ 0.73 | 2.83 % | $ 34.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | Canada |
 |
Tandem Diabetes Care
TNDM
|
-205 M | $ 19.5 | 2.58 % | $ 1.33 B | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Viemed Healthcare
VMD
|
14.9 M | $ 11.67 | -0.77 % | $ 454 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 14.94 | 2.47 % | $ 423 M | USA |
 |
Varex Imaging Corporation
VREX
|
-70.3 M | $ 11.19 | 1.08 % | $ 463 M | USA |
 |
Avanos Medical
AVNS
|
-72.9 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Inogen
INGN
|
22.7 M | $ 6.45 | 0.47 % | $ 172 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.36 | 3.08 % | $ 22.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 0.82 | -1.39 % | $ 13.9 M | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 121.21 | 20.18 % | $ 4.21 B | USA |
 |
Beyond Air
XAIR
|
-33.2 M | $ 5.28 | -2.68 % | $ 43.8 B | USA |
 |
Xtant Medical Holdings
XTNT
|
4.97 M | $ 0.43 | -0.6 % | $ 60 M | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 80.14 | -1.12 % | $ 4.37 B | Britain |
 |
NanoVibronix
NAOV
|
-18.2 M | - | - | $ 1.08 M | USA |